冷冻干燥药物、重组器材和注射市场：产品、市场、疗法、策略和预测

Lyophilized Drugs, Reconstitution Devices and Injection Markets: Products, Markets, Therapeutics, Strategies & Forecasts

出版日期: 2024年07月31日 | 出版商:

Greystone Research Associates | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

近年来，以冷冻干燥製剂形式输送的药物数量持续增加，反映出生物製剂的不断增加。需要冷藏直至配药（称为冷链）的液体药物可以配製为粉末，以避免冷藏成本和物流。有许多因素将影响未来对冷冻干燥药物的需求。也许最重要的是製药和生物技术市场的潜在动态，因为它们适用于药物配方和最终用户的要求。

本报告研究了冷冻干燥药物、重组器材和注射剂市场，并提供了市场概况、治疗需求趋势、到2026年的市场资料和预测以及市场参与者的概况。

用于 POC 重新配置的整合设备
双室筒匣
双室注射器
双室注射器
穿戴式装置自动重新设定係统
设备评估
产品特定设备
MiniQuick（Vetter）
特殊设备
Caverject Impulse（Hospira/Pfizer）
OEM 设备
Lyoject（Vetter）
DCP（SHL）
Dual Chamber Safety Syringe（Credence Medsystems）
Liquid Dry（Becton Dickinson）
LyoTwist Trio/Vario（Ypsomed）
LyoTwist Trio S/Vario S（Ypsomed）
V-LK（维特尔）
市场机会
冷冻干燥药品市场动态
冷冻干燥药物的经济学
是什么推动了冻干药品市场的发展？
自我管理的趋势
人口统计变化
一次性设备设计的创新
竞争状况
推动治疗需求的因素
风险因素
冷冻-冷冻干燥药物 - 初级包装
药物重构
双室筒匣
双室注射器
预充填稀释剂注射器
多步骤装置
人体工学
重点治疗领域分析及市场资料
抗生素和感染
免疫
心臟病学和血液因素
代谢状态
血糖控制
开发阶段双室注射
骨质疏鬆症
荷尔蒙
神经病学
肿瘤学
生殖健康
勃起功能障碍
市场因素
监理问题
医疗保健经济
治疗领域 - 资料和预测
荷尔蒙替代疗法
Genotropin（Pfizer）
代谢状态
骨质疏鬆症
神经病学
Abilify Maintena（Otsuka America Pharmaceutical）
肿瘤学
Luclin（Abbott Australasia Pty）
生殖健康
Caverject Impulse（Hospira/Pfizer）
Edex/alprostadil（Actient）
Lupron Depot（AbbVie）
其他治疗领域
Prostap（Takeda）

公司简介

简介目录

"Lyophilized Drugs, Reconstitution Devices, and Injection Markets: Therapeutics, Strategies and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for lyophilized injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

The number of drugs supplied in lyophilized form has been growing at an increased rate over the past several years, mirroring the increase in the introduction of biological drugs. Liquid drugs that require refrigeration until dispensed - a requirement referred to as the 'Cold Chain' - can be formulated as powders to avoid the cost and logistics of cold storage. A number of factors are at play that are likely to influence the future demand picture for lyophilized drugs. Perhaps the most important is the underlying dynamics of the pharmaceutical and biotechnology marketplace as they apply to drug formulation and end user requirements.

What You Will Learn:

Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
Analyzes reconstitution technologies and market development issues
Provides market data and forecasts to 2026
Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
Assesses the importance of technology and regulatory factors on commercialization and market access